The best treatments require a complete understanding of human health and disease. Research has been the epicenter of our world-renowned patient care for more than a century.
Lerner Research Institute's 1,800+ caregivers strive to improve the lives of patients today and in the future, locally and globally.
Researching for Health
Home to 240 labs transforming $435m* annual funding into leading-edge research.
*2023 yearly research funding
Educating Those Who Serve
650+ trainees at Lerner Research Institute, from high school students to postdoctoral fellows, are studying everything from molecular medicine to biomedical engineering.
We ask the big questions.
Cleveland Clinic's Lerner Research Institute is home to basic, translational and clinical researchers. Our curiosity fuels discovery with patient care in mind. We challenge assumptions. We ask the big questions.
Lerner Research Institute respects and appreciates its diverse community. Putting inclusion first while embracing both similarities and differences equips us to ask informed questions about human health and disease. Ultimately, this range of perspectives helps to better solve community-wide healthcare issues. Our commitment to a diverse and dynamic workforce helps us reflect the communities we serve.
Every disease treatment, biomarker and diagnostic used by a clinician today was first researched and developed by scientists in a laboratory years—sometimes even decades—earlier. With a legacy of innovation, researchers in Cleveland Clinic laboratories have contributed to many such discoveries that have changed modern medicine, including:
1932Dr. Roy McCullagh posited the existence of inhibins (important proteins related to sex hormones and reproductive health), pioneering the early ideas that led to their isolation decades later.
1948
Dr. Irvine Page, Cleveland Clinic’s inaugural Director of Research, and collaborators Drs. Arda Green (pictured) and Maurice Rapport isolated the hormone serotonin, a discovery that served as the basis of much modern brain chemistry research and treatment.
1950sDr. Willem Kolff (at left leaning on the patient's bed) perfected his kidney dialysis machine, the first “artificial kidney” ever to be developed. Utilizing his machine, Cleveland Clinic was the first site in the United States to make kidney dialysis available to patients. Also during Dr. Kolff’s tenure, he helped to develop heart-lung machines to maintain cardiac and respiratory functions during cardiac surgery.
1957
Dr. F. Merlin Bumpus synthesized angiotensin-II, a vasoconstrictor that helps to increase blood pressure. Its naturally occurring form was first isolated in the blood by Dr. Irvine Page 12 years earlier. Both leaders in the field of hypertension research, their discoveries laid the foundation for many anti-hypertensive therapies.
1960Dr. Irvine Page (pictured left), with the help of Drs. Helen Brown (pictured right) and Jerome Green, served as the national leader of the National Heart-Diet Study (funded by the National Institutes of Health), which ran until 1965 and was the country’s first large study to investigate the connection between lipids (dietary fat) and atherosclerosis. The study, whose diet was designed to reduce dietary cholesterol in an effort to curb heart and vascular disease, was revolutionary in bringing modern ideas on a healthy diet to the American public.
1960s
Dr. Harriet Dunstan was among the first to recognize and describe renal arterial hypertension (high blood pressure due to narrowing of the arteries that carry blood to the kidneys). Together with Dr. Eugene Poutasse, the two pioneered renal vascular surgery to combat renal hypertension.
1990
Dr. Subha Sen isolated and purified myotrophin, a protein intimately linked with cardiac hypertrophy and which can cause heart failure.
2000s
Drs. Charis Eng (pictured) and Rosemary Teresi identified a new class of molecules involved in thyroid cancer, a discovery which laid the groundwork for the development of the first molecular test for thyroid cancer in 2008.
2010
Dr. Vincent Tuohy published results of a successful preventive breast cancer vaccine in mice. He is still working today to advance this vaccine for use in patients.
2013
Dr. Edward Plow discovers that foam cells—a hallmark of atherosclerosis—are regulated by the blood protein plasminogen.
2013
Dr. Nima Sharifi discovered a gene variant that renders androgen-deprivation therapy (or medical castration) ineffective for men with prostate cancer and leads to the development of more aggressive, treatment-resistant cancer.
2016
Dr. Stanley Hazen (pictured middle) found in a landmark study that TMAO—a dietary-linked, gut microbe-produced metabolite—alters platelet function and increases risk for heart attack and stroke. In a subsequent study published in 2018, Dr. Hazen designed a potential new class of drugs that may reduce cardiovascular disease risk by blocking this microbial pathway in the gut, the most potent therapy to date that works by “drugging” the microbiome.
2017
Research engineer Karl West (pictured right) developed imaging software using Microsoft HoloLens technology that was used in the world’s first total face transplant, enabling surgeons to visualize in 3-D how to overlay the donor and recipient’s facial anatomy.
2018
Dr. Paul Marasco engineered a new method that utilizes strategic muscle vibration to restore natural movement sensation in patients with prosthetic arms, also providing improved spatial awareness and fine motor control without requiring patients to visually monitor the prosthesis.
2018
Dr. Bruce Trapp (pictured right) discovered a novel subtype of multiple sclerosis, one that uniquely features neuronal loss but no white matter demyelination, which is a hallmark feature of the more traditional form of the disease.
Support Ground-Breaking Research
The future of health starts with your support. Donations supply researchers with the tools, space and staff they need to think big.